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Context: Brain white matter hyper-intensities are seen on routine clinical imaging in 46% of 
adults with congenital adrenal hyperplasia (CAH). The extent and functional relevance of these 
abnormalities have not been studied using quantitative MRI analysis.  
Objective: To examine white matter microstructure, neural volumes and CNS metabolites in 
CAH due to 21-hydroxylase deficiency (21OHD) and to determine whether identified 
abnormalities are associated with cognition, glucocorticoid and androgen exposure. 
Design, setting and participants: A cross-sectional study at a tertiary hospital including 19 
females (18-50 years) with 21OHD and 19 age-matched healthy females. 
Main outcome measure: Recruits underwent cognitive assessment and brain imaging including; 
diffusion weighted imaging of white matter, T1-weighted volumetry and magnetic resonance 
spectroscopy for neural metabolites. We evaluated white matter microstructure using tract-based 
spatial statistics. We compared cognitive scores, neural volumes and metabolites between groups 
and relationships between glucocorticoid exposure, MRI and neurologic outcomes.   
Results: Patients with 21OHD had widespread reductions in white matter structural integrity, 
reduced volumes of right hippocampus, bilateral thalami, cerebellum and brainstem, and reduced 
mesial temporal lobe total choline content. Working memory, processing speed, and digit span 
and matrix reasoning scores were reduced in patients with 21OHD, despite similar education and 
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intelligence to controls. 21OHD individuals exposed to higher glucocorticoid doses had greater 
abnormalities in white matter microstructure and cognitive performance. 
Conclusion: For the first time we demonstrate that 21OHD and current glucocorticoid 
replacement regimens have a profound impact on brain morphology and function. If reversible, 
these CNS markers represent a potential target for treatment. 
Using quantitative neuroimaging and cognitive assessment, Webb et al demonstrate that 21OHD and 
current glucocorticoid replacement regimens have a profound impact on brain morphology and function. 
Introduction 
Steroid hormones regulate CNS development, exerting trophic effects on cell survival, 
differentiation, maturation and synaptogenesis (1,2). The most common variant of the inborn 
steroidogenic disorder congenital adrenal hyperplasia (CAH), 21-hydroxylase deficiency disrupts 
adrenal steroidogenesis at critical branch points of glucocorticoid (cortisol) and 
mineralocorticoid (aldosterone) synthesis. Reduced glucocorticoid feedback to the hypothalamo-
pituitary axis results in increased central stimulation of adrenal steroidogenesis. This leads to; 
increased adrenal androgen production and subsequent systemic androgen excess, glucocorticoid 
deficiency and, in two-thirds of patients, clinically apparent mineralocorticoid deficiency (3). 
Medical treatment aims to replace the deficient hormones and to limit exposure to androgen 
excess. However, in clinical practice, patients are frequently exposed to significant degrees of 
both glucocorticoid and androgen excess (3). CAH therefore provides a pathophysiological 
model suited to study the impact of fluctuations in glucocorticoid and androgen exposure on 
human brain structure and function. 
Qualitative evaluation of structural T2-weighted MRI studies in patients with CAH provides 
evidence white matter hyper-intensities (leukoaraiosis) in up to 46% of patients (4,5) 
predominantly located in the temporal lobe, amygdala, hippocampus, periventricular and corpus 
callosum. Leukoaraiosis is an uncommon incidental finding in healthy adults aged <45 years (6). 
The pathophysiology of leukoaraiosis remains poorly defined (7); however, the presence of local 
white matter abnormalities appears to be indicative of a global dysregulation of white matter 
structure, with changes in white matter microstructure in affected individuals not only localised 
to those areas of abnormality identified on visual inspection (8). Diffusion weighted imaging a 
non-invasive MRI technique, provides quantitative indices of brain development, enabling the in 
vivo examination of white matter microstructure and characterization of white matter anatomy 
including the degree of connectivity between different regions of the brain (9,10). In pathologic 
conditions, diffusion anisotropy of water molecules is reduced because of altered diffusivity and 
disorganization of the white-matter fibres. These measurements may become abnormal even 
before the lesion is morphologically apparent on conventional MRIs, helping both with early 
detection and with defining the extent of lesions. We hypothesized that diffusion tensor imaging 
(DTI) would identify significant reductions in quantitative indices of white matter microstructure 
in patients with CAH, including mean diffusivity, which reflects the degree of water mobility, 
and fractional anisotropy, which is affected by axonal caliber, fibre density and degree of 
myelination  (11). 
Measurements of in-vivo human brain volumes can provide novel insights into the 
pathophysiology of patients’ cognitive abnormalities with neuroimaging increasingly used in clinical 
trials as a biomarker to study the impact of treatment modifications. The extent of volumetric 
abnormalities present in patients with CAH has not previously been investigated using high 
resolution MRI in conjunction with automated quantitative data analysis. In view of the high 
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concentrations of androgen, mineralocorticoid and glucocorticoid receptors in the hippocampus, 
amygdala, thalamus, brainstem and cerebellum (2,12-14), we hypothesized that patients with 
CAH would have localized volume loss in these regions. 
Magnetic resonance spectroscopy (MRS), which enables the in vivo measurement of cerebral 
metabolites, provides a sensitive tool to measure the impact of changes in steroid hormone 
exposure on the brain. It has previously been used to investigate how excess glucocorticoid 
exposure affects cerebral metabolite concentrations in patients with Cushing’s disease (15). 
Patients with Cushing’s syndrome have reduced total choline, with normalization of the brain 
metabolite ratios following resolution of Cushing’s disease (15). MRS has not previously been 
performed in patients with CAH in whom we hypothesized that total choline would be reduced. 
Glucocorticoids exert an inverted U-shape influence on human cognition, in particular on 
acquiring and consolidating memory (2) whereas androgens have an overall beneficial effect on 
cognitive control, verbal memory and spatial cognition in humans (1,13,16). Whilst previous 
studies in patients with CAH have consistently identified impairments in short-term and working 
memory performance, thought to relate to excess glucocorticoid exposure, the relationship 
between these cognitive abnormalities and changes in brain structure have not previously been 
investigated (17). We hypothesized that neural abnormalities would correlate with cognitive 
performance, and that increased glucocorticoid exposure would be associated with poorer 
performance on neuropsychometric tests, reductions in neural volumes, fractional anisotropy and 
total choline.  
Subjects and methods 
Patient selection 
Adult women with CAH due to 21-hydroxylase deficiency diagnosed by hormonal and genetic 
testing were recruited from the endocrine clinic at University Hospital Birmingham and via the 
patient support group CLIMB, Living with CAH. Local advertisements were placed within 
University Hospital Birmingham NHS Foundation Trust to recruit control subjects. Exclusion 
criteria for both groups were pregnancy, hypothyroidism, a medical condition known to affect 
cerebral anatomy or metal in the body. Additional exclusion criteria for the control group were 
diagnosed psychiatric disorder, glucocorticoid use (ever) or diagnosed learning disabilities. The 
study was approved by the national research ethics committee West Midlands and all participants 
gave written informed consent prior to participation. 
Ethnicity, age at diagnosis, handedness, highest educational level, employment category and 
current glucocorticoid replacement dose were recorded. The genotype of patients with 21OHD 
was classified into genotype groups null, A, B, and C (18). In patients taking prednisolone 
instead of hydrocortisone, the equivalent dose was calculated by multiplying total prednisolone 
dose by four (19). Educational status was graded 1-6 based on the participant’s highest level of 
educational achievement (1. Completed primary school, 2. Completed middle school to age 16 
years, 3. Completed high school to age 18 years, 4. Higher studies beyond school, 5. Degree, 6. 
Post-graduate degree). All participants with CAH had fasting 9:00-11.00h blood samples taken 
on the day of MRI acquisition prior to any medication for measurements of plasma renin 
concentration, serum 17-hydroxyprogesterone (17-OHP), DHEAS, androstenedione and 
testosterone liquid chromatography and tandem mass spectrometry. Standing height was 
measured with a stadiometer.  
Psychometric assessment 
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Psychometric testing comprising Wechsler Adult Intelligence Scale (WAIS) IV and Wechsler 
Memory Scale (WMS) IV assessments was administered by a trained psychology research 
assistant (20,21).  
Health-related quality of life and mood questionnaires 
All study participants completed the World Health Organization Quality of Life, (WHOQOL) 
and Hospital Anxiety and Depression Scale (HADS) questionnaires (22,23). WHOQOL is an 
instrument to assess general well-being and comprises 26 items to broadly measure 4 domains; 
physical health, psychological health, social relationships and environment. The HADS 
questionnaire is a 14-scale questionnaire that is used to ascertain the levels of depression and 
anxiety that a subject is experiencing. 
MRI acquisition 
MR imaging was performed on a 3 T Philips Achieva scanner using a 32-channel head coil. One 
neuroradiologist (VS) blinded to the clinical data reviewed all images. DTI was performed using 
a monopolar Stejskal-Tanner sequence over 61 directions, with a single b=0 image and b-factor 
of 1500 s/mm2. Data was collected in the axial plane, with an imaging matrix of 112x112 over 
72 slices at an isotropic resolution of 2 mm. An echo time of 78 ms was used with a SENSE 
parallel imaging factor of 2. High-resolution 3D T1-weighted images were acquired (TR = 8.40 
msec, TE = 3.8 msec, flip angle = 8°, FOV = 288 mm, 175 slices, 2 mm isotropic voxels). MRS 
data was acquired from an 18x18x18 mm voxel in the left mesial temporal lobe and a 20x20x20 
mm voxel in the right parietal lobe. Point-resolved spectroscopy was performed at 3 T, with an 
echo time of 35 ms, a repetition time of 2000 ms and 128 repetitions. A water unsuppressed 
MRS was acquired from the same voxel for water referencing. 
Image Analysis 
Diffusion-weighted images were initially processed using the Functional Magnetic Resonance 
Imaging of the Brain Software Library (FSL; http://www.fmrib.ox.ac.uk/fsl). Data were inspected 
for movement artifacts and then corrected for eddy current induced distortions. Brain extraction 
and calculation of diffusion tensor fractional anisotropy and mean diffusivity maps were carried 
out using FSL tools. Fractional anisotropy and mean diffusivity images were processed using 
tract-based spatial statistics (TBSS) and automated, observer-independent, voxel-by-voxel 
whole-brain between-group analysis performed (corrected for age) (24). Initially, every 
fractional anisotropy image was aligned to the FMRIB58 standard space fractional anisotropy 
map. Secondly the mean fractional anisotropy image across subjects was created. The mean 
image was thinned and thresholded at a fractional anisotropy value of 0.2 to create a white matter 
tract skeleton representing the center of the tracts common to all subjects. Fractional anisotropy 
data projected onto these skeletons was used in voxel-wise statistical comparisons using the 
Threshold-Free Cluster Enhancement option (corrected for multiple comparisons across space). 
Amygdala, hippocampus, thalamus, cerebellum, brainstem, CSF and total brain volume were 
determined from the T1-weighted MRI using Freesurfer, an automated segmentation tool (25). 
We selected the structures in the brain with the highest concentration of androgen, 
mineralocorticoid and glucocorticoid receptors (2,12-14). No other neural volumes were 
extracted from the Freesurfer analysis to ensure all analyses performed were hypothesis-driven. 
Spectroscopy data were analyzed using the TARQUIN algorithm version 4.3.7 to obtain 
concentrations for Glutamate, total NAA (N-acetylaspartate and N-acetylaspartylglutamate, total 
choline (glycerophosphocholine and phosphocholine), total creatine (Creatinine and 
phosphocreatine) and Glx (glutamine plus glutamate) (26). Since voxels tended to contain grey 
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matter, white matter and CSF in varying proportions, each voxel was segmented and the 
metabolite concentrations corrected for the differing water content (27).  
Statistical analysis 
The current study was powered to detect a 20% difference (SD 0.36) in amygdala volume 
(power=0.85, α=0.05) between patients and controls (28). As the previous published 
neuroimaging study included only females with CAH (28), and there is a well described sexually 
dimorphic pattern of brain development (29), all study recruits to the current study were female. 
Baseline characteristics of the two groups were compared using unpaired Student’s t test. 
Behavioral, quality of life and cognitive assessment scores were compared between patients with 
CAH and controls using ANCOVA corrected for education level. Correlations were performed 
to assess the relationships of markers of androgen and glucocorticoid exposure with 
psychometric assessment scores in patients with CAH. Data was analyzed using SPSS version 
22.  
Total brain, CSF volume and cerebral metabolite concentrations were compared between 
patients with CAH and controls using ANCOVA, with age as a covariate. For all other neural 
volumes, total brain volume was an additional covariate, p-values were adjusted to control for 
false discovery rate (FDR) (30).   
Partial correlations were used to assess the relationship between neural volumes and 
metabolite concentrations, when initial results indicated that there was a significant difference in 
neural volume/metabolite concentration between the two groups), and neuropsychometric scores 
in patients with CAH, p-values adjusted for FDR (30). For neural volumes, correlations were 
also controlled for total brain volume. Correlations were used to assess the relationship between 
markers of androgen and glucocorticoid exposure, neural volumes, fractional anisotropy and 
mean diffusivity and metabolite concentrations, (where there was a significant difference in 
neural volume/metabolite concentration between the two groups) in just patients with CAH, 
adjusted for FDR (30); Variables examined were those that showed a significant difference 
between CAH patients and controls in group analyses. 
Results 
Study cohort characteristics 
 Nineteen adult women (mean 30.6 years, range 18-49) with 21-hydroxylase deficiency 
receiving glucocorticoids (median hydrocortisone dose 11.1mg/ m2/day; range 10-13.8) and 
nineteen healthy women (mean 32.8 years, range 21-50) were recruited between July 2015-
September 2016 (Table 1). All participants were right-handed, had no abnormal neurological 
findings and had completed mainstream schooling. All patients had 21-hydroxylase deficiency 
confirmed by molecular genetic analysis. Genotype groups null, A, B, and C contained 74%, 
10.5%, 10.5%, and 5% of the patients, respectively (18), which means that the large majority of 
patients had a classic salt-wasting phenotype. One patient had non-classic CAH. Median age at 
diagnosis with 21-hydroxylase deficiency was 2 weeks (range birth-17 years). Sixteen out of 19 
patients with CAH also had mineralocorticoid deficiency and were on fludrocortisone 
replacement (median dose 150mcg) at the time of assessment. Eight patients were taking 
prednisolone and 11 were taking hydrocortisone, the largest dose was taken in the morning in all 
patients. Fifteen of 19 patients with CAH had been on the same glucocorticoid dose for ≥3 years. 
No patients with CAH were taking the oral contraceptive pill. 
 One individual with CAH was unable to complete the WAIS due to time constraints.  
One individual with CAH and one control did not tolerate the MRI scan but completed all other 
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study components. MRI data quality was adequate in all subjects (VS). Temporal voxel MRS 
spectra were deemed to be suitable for analysis in 17 patients with CAH and 16 controls and 
parietal voxel spectra were deemed to be suitable for analysis in 18 patients with CAH and 17 
controls, as judged by visual inspection by two independent observers (AP, DC). 
Psychometric assessment  
 The physical component of QOL was significantly reduced in patients with CAH compared with 
controls (p<0.001) (Table 2). Patients with CAH scored higher on the depression component of 
the HADS questionnaire, however no-one scored in the clinical range (p=0.02) (Table 2).  
There was no significant difference in full-scale IQ between patients with CAH and controls. 
When compared to controls patients with CAH had significantly reduced: working memory 
index (p=0.04), processing speed (p=0.03), digit span (p=0.04) and matrix reasoning scores 
(p=0.03) (Table 3).  
CNS abnormalities in patients with CAH  
 Four of 19 CAH patients (21%) had a type 1 Chiari anomaly; brain MRI was otherwise 
normal on visual inspection in all subject. In none of the study participants a pituitary gland 
abnormality was reported; however, specific pituitary views were not acquired. 
Widespread reductions in fractional anisotropy were present in the superior longitudinal 
fasciculus, inferior fronto-occipital fasciculus, corticospinal tract, uncinated fasciculus, cingulate 
gyrus, the hippocampus and the corpus callosum in patients with CAH (p<0.05) (Fig. 1). Mean 
diffusivity was increased bilaterally in the superior and inferior longitudinal fasciculus, inferior 
fronto-occipital fasciculus, anterior thalamic radiation, the corticospinal tract, the uncinate 
fasiculus, the cingulate gyrus and the hippocampus in patients with CAH (p<0.05).  
Although CSF volume was significantly increased in patients with CAH (p=0.003), total 
brain volume was not significantly different between patients with CAH and controls. After 
correction for multiple comparisons localised reductions in neural volumes were present in 
patients with CAH in the right hippocampus, left and right thalami, the cerebellum and the 
brainstem (p=0.028, 0.007, 0.008, 0.014, 0.03 respectively) (Table 4).  
 There were no significant differences in metabolite concentrations between patients with 
CAH and controls in the parietal voxel. In the mesial temporal voxel, total choline and total 
creatine were significantly lower in patients with CAH than controls (p=0.001 and p=0.04 
respectively) (Table 4). Only total choline remained significantly reduced after correction for 
multiple comparisons. 
Correlations between MRI findings and cognitive assessment scores in patients with CAH  
There were significant correlations between cerebellar volume and matrix reasoning scores 
(r=0.7, p=0.002, Fig. 2A), and between brainstem volume, working memory performance and 
digit span scores (r=0.6, p=0.009, r=0.59, p=0.01 respectively, Fig.  2B and C). Spectroscopy-
acquired left mesial temporal lobe total choline correlated significantly with working memory 
index (r: 0.62, p=0.01, Fig. 2D). There were no significant relationships between fractional 
anisotropy and mean diffusivity and cognitive assessment scores.  
Correlations between markers of glucocorticoid and androgen exposure, MRI findings and cognitive 
assessment scores in patients with CAH  
Increased glucocorticoid equivalent dose (mg) correlated significantly with reduced working 
memory (r: -0.52, p=0.03) and digit span scores (r: -0.51, p=0.03) (Fig. 2E and 2F). There were 
no significant relationships between markers of androgen exposure and psychometric assessment 
scores. 
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Higher hydrocortisone equivalent dose (mg) correlated significantly with reduced mesial 
temporal lobe total choline (r: -0.72, p=0.001, Fig. 2G) and mean diffusivity (r: -0.5, p=0.03, 
Fig. 2H), suggesting that patients exposed chronically to higher glucocorticoid doses have 
greater reductions in mesial temporal lobe total choline and white matter microstructure, 
reflected by total choline concentration and mean diffusivity. There were no significant 
differences in any of the cognitive or MRI abnormalities identified between those individuals 
taking prednisolone and those prescribed hydrocortisone. There were no significant associations 
between markers of androgen exposure, MRI and cognitive findings. 
Discussion 
 Using multiple quantitative imaging modalities in conjunction with neuropsychological 
assessment enabled us to identify functionally significant biomarkers of the disease process 
(CAH) and treatment effects (steroid exposure) in patients with CAH. Patients had global 
abnormalities of cerebral white matter with localized reductions in neural volumes in regions of 
the brain that have previously been documented to contain high concentrations of androgen, 
mineralocorticoid and glucocorticoid receptors (2,12-14). The mesial temporal lobe was affected 
bilaterally with significant reductions in white matter microstructure, right hippocampal volume 
and left mesial temporal lobe choline. Interestingly, whilst markers of androgen exposure did not 
relate to the identified CNS abnormalities, exposure to higher glucocorticoid doses was 
associated with significantly worse cognitive performance and abnormal mesial temporal lobe 
total choline and white matter mean diffusivity.  
Concordant with finding of previous studies (17,31), we found reduced working memory and 
digit span scores and impaired quality of life. Whilst we had a priori hypotheses that working 
memory, processing speed and digit span would be reduced in patients with CAH based on 
previous studies these differences did not remain after controlling for multiple comparisons 
(17,32). Cognitive abnormalities in patients with CAH may relate to the supra-physiological 
glucocorticoid doses used to supress adrenal androgen production (17). In support of this 
hypothesis working memory, episodic and declarative memory are adversely affected in patients 
treated with exogenous glucocorticoids, in adults with Cushing’s syndrome producing excess 
endogenous glucocorticoids and in healthy human volunteers given glucocorticoids (33,34). Our 
data provide further evidence that cognitive abnormalities present in patients with CAH relate to 
the degree of glucocorticoid exposure, with those patients on higher current glucocorticoid doses 
having significantly worse performance on working memory and digit span tests. 
We identified an increased prevalence of type 1 Chiari anomalies in patients with CAH, 
similar to a previous study of adults with CAH in which 8 of the 39 patients studied had type 1 
Chiari anomalies (4). Chiari anomalies are a complex developmental disorder characterized by 
primary axial skeletal defects and secondary neurological anomalies involving the craniocervical 
region (35). We found the cerebellum and hindbrain to be smaller in patients with CAH 
suggesting that the downwards displacement of the cerebellar tonsils does not relate to brain 
structural abnormalities. It is possible that in patients with CAH exposure to steroid hormone 
abnormalities early in embryonic development may affect occipital bone formation antenatally 
(35).  The relevance of this increased prevalence of type 1 Chiari anomalies to the clinical course 
and ongoing management in patients with CAH remains to be elucidated. 
Patients with CAH are exposed to multiple potentially pathological hormone abnormalities 
and the neural changes we describe are likely to be multifactorial. Hypoglycemia and salt loss at 
initial presentation and subsequently at the time of adrenal crisis are likely to affect brain 
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structure. We were unable to examine the difference in CNS changes between patients with and 
without mineralocorticoid deficiency due to the small number of patients without salt loss 
recruited to the study. However, we identified no reduction in full scale IQ in our patients with 
CAH, in contrast to previous studies that report reduced full scale IQ in patients with a history of 
salt wasting crises requiring inpatient hospital management (36). Future studies should aim to 
dissect the impact of salt wasting on the CNS by including patients with conditions such as 
isolated aldosterone synthase deficiency. 
Gross structural brain white matter abnormalities have been described previously in patients 
with CAH, in conjunction with thinning of the corpus callosum and small volume hippocampi 
(4,37). However, for the first time we have identified significant widespread abnormalities in 
white matter microstructure in patients with CAH. As longitudinal DTI studies report corpus 
callosum fractional anisotropy to be higher in men than in women, our findings with regard to 
white matter microstructure are unlikely to be due to excess androgen exposure (38). Animal and 
human disease models provide some evidence to suggest that the abnormalities we describe 
relate to glucocorticoid treatment in patients with CAH. In animal models prolonged exposure to 
raised glucocorticoid concentrations leads to the inhibition of oligodendrocyte precursor 
proliferation, negatively impacting on myelin production (39). Patients with Cushing’s disease 
have significant reductions in fractional anisotropy and increases in mean diffusivity throughout 
the brain (40). Importantly; partial resolution of neuritic degenerative changes in rodents, 
significant improvements in cognitive function and reversal of cerebral atrophy in humans occur 
following withdrawal of glucocorticoids, suggesting that modification of treatment regimens in 
patients with CAH may positively impact on myelination and cognitive function (41).  
In contrast to the expected finding of increased amygdala volume in girls with CAH exposed 
to excess androgens antenatally Merke et al identified smaller amygdala volumes using a manual 
tracing method with volumetric MRI acquisition on a 1.5 T (28). This was interpreted as an effect 
of postnatal excess glucocorticoid exposure in patients with CAH. Whilst we did not replicate 
this result, our findings of localized volume loss in the right hippocampus, the left and right 
thalami, the cerebellum and the brainstem also differs from the pattern of larger limbic, insula 
and occipital lobe volumes, and smaller parietal lobe and opercular left inferior frontal gyrus 
volumes seen in association with increased testosterone exposure (1,13,16,36,42).  
Mineralocorticoid receptors, which have a similar affinity for cortisol and aldosterone, are 
located in limbic structures, in particular in the hippocampus, while being almost absent 
elsewhere in the brain (14). Neurons in the hippocampus do not express 11β-hydroxysteroid 
dehydrogenase type 2, which elsewhere in the body converts corticosterone and cortisol into 
inactive metabolites. Therefore, in the hippocampus, the mineralocorticoid receptor is mainly 
considered to be a glucocorticoid-activated receptor; making the hippocampus selectively 
vulnerable to non-physiological fluctuations in glucocorticoid concentrations (14). 
Glucocorticoids increase excitatory amino acids and serotonin concentrations leading to neural 
damage (33) and may also increase the vulnerability of neurons to other insults such as ischemia, 
via reduced neuronal glucose uptake (43). Administration of oral hydrocortisone in humans leads 
to reduced hippocampal metabolism, (44) and patients with Cushing’s syndrome, exposed 
chronically to high glucocorticoid concentrations, have localized volume loss in the 
hippocampus and temporal lobes (41). The cerebellum, which we found to be significantly 
smaller in patients with CAH, has the highest concentration of CNS glucocorticoid receptors (12) 
with exogenous glucocorticoids impacting negatively on cerebellum growth in mice (45). Whilst 
the current study design does not enable us to determine the exact etiology of the structural 
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impairments identified, the reductions in neural volumes in regions of the brain with high 
concentrations of glucocorticoid receptors, in areas shown to be affected negatively by increased 
glucocorticoid exposure in in vivo and murine studies suggests that the brain abnormalities we 
describe in patients with CAH relate to chronic excess glucocorticoid exposure. These findings 
require replication in larger, independent samples. 
We identified a reduction in total choline, a marker of CNS myelination, inflammation and 
membrane synthesis and repair in CAH patients, which did not extend to the right parietal lobe. 
Exposure to higher glucocorticoid doses was significantly associated with mesial temporal lobe 
total choline. This suggests that reduction in total choline in the hippocampal voxel relates to 
raised glucocorticoid concentrations in patients with CAH as the mesial temporal lobe contains 
high concentrations of glucocorticoid receptors (2). Khiat et al identified a reduction in choline 
resonance in 13 patients with Cushing’s syndrome in frontal and thalamic areas (15), 
hypothesized to reflect an inhibition of phospholipase A2 activity by glucocorticoids; 
phospholipase A2 hydrolyzes specific ester bonds in membrane phospholipids (46). Importantly 
following normalization of cortisol concentrations, improvements in memory and the brain 
metabolite profile were documented (15).  
Conclusion 
CAH has a profound impact on normal brain and cognitive development with the effects we 
describe most marked in the mesial temporal lobe. We also describe a significant association 
between current glucocorticoid replacement regimens, cognitive and central nervous system 
abnormalities. Whilst we are not able to control for previous episodes of hypoglycemia and salt 
loss at initial presentation and subsequently during adrenal crisis incidents, the recent 
development of more physiological glucocorticoid replacement regimens and other modalities 
which offer improved control of altered steroidogenesis in CAH (3) may provide opportunities to 
use the biomarkers identified in the current study (mean diffusivity, mesial temporal lobe total 
choline) to assess the impact of novel treatments on the CNS in patients with CAH. These 
findings are also relevant to the wider population of whom 1% are on long-term glucocorticoid 
therapy (47).  
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Figure 1  The association between congenital adrenal hyperplasia and fractional anisotropy (tract 
based spatial statistics analysis comparing patients with congenital adrenal hyperplasia to healthy 
controls). The association between congenital adrenal hyperplasia and white matter skeleton 
fractional anisotropy (FA). Mean FA skeleton overlaid on the mean FA map. Regions of the 
mean FA skeleton in green represent areas where there were no significant differences in FA 
values in the patients with congenital adrenal hyperplasia patients compared to healthy controls. 
Areas in red/yellow are regions where the FA was significantly lower in the congenital adrenal 
hyperplasia group, and can be observed bilaterally in the superior longitudinal fasciculus, inferior 
fronto-occipital fasciculus, corticospinal tract, uncinate fasciculus, cingulate gyrus, the 
hippocampus and the corpus callosum (p<0.05).  FA is a dimensionless index. 
Figure 2 The association between cognitive function scores and neural volumes, hydrocortisone 
equivalent dose; cognitive function scores, mesial temporal lobe total choline and mean 
diffusivity in adults with congenital adrenal hyperplasia. Partial correlations were used to assess 
the relationship between neural volumes and metabolite concentrations and neuropsychometric 
test results for WAIS and WMS assessments in patients with congenital adrenal hyperplasia. For 
neural volumes, correlations were also controlled for total brain volume. Correlations were used 
to assess the relationship between markers of androgen and glucocorticoid exposure, neural 
volumes, fractional anisotropy and mean diffusivity and metabolite concentrations, in patients 
with congenital adrenal hyperplasia. All p-values were adjusted to control for false discovery rate 
(30).  
Table 1: Age, auxology, educational level, glucocorticoid dose and fasting steroid hormone 
concentrations 
 CAH Controls p-
value 
Number 19 19  
Mean Age (years) (SD, SE) 30.6 (8.9, 2) 32.8 (8.5, 2) 0.4 
Mean Height (cm) (SD, SE) 158.3 (8.3, 1.9)  164.9 (5.9, 1.4)  0.008* 
Mean Weight (kg) (SD, SE) 77.1 (16.1, 3.7) 73.9 (17.8, 4.2) 0.57 
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14 
Mean BMI (SD, SE) 30.9 (6.5, 1.5) 27.1 (6.1, 1.4) 0.08 
Mean Head circumference (cm) (SD, SE) 55.2 (2.6, 0.6) 55.7 (2.1, 0.5) 0.6 
Type 1 Chiari anomaly 4 0  
Mean Educational level (Graded 1-6) (SD, SE) 4.3 (1.3, 0.3)  4.3 (1.2, 0.3) 0.9 
CAH patients only Median (Q1-Q3)  Reference range  
Mineralocorticoid dose (mcg/day) 150 (100-237) N/A  
Glucocorticoid equivalent dose (mg/m2day)** 11.1 (10-13.8) N/A  
Glucocorticoid equivalent dose (mg/day) 20 (16-25) N/A  
Plasma Renin concentration 27 (13-48) 1.8-59.4ng/L  
Serum 17-hydroxyprogesterone  62 (2-168) 0.6-6nmol/L  
Serum DHEAS  0.54 (0.2-2.6) 2.68-9.23nmol/L  
Serum Androstenedione  7.7 (3.2-15.3) 0.9-7.5nmol/L  
Serum Testosterone 1.9 (0.8-2.9) <1.9nmol/L  
*p-values remain significant after controlling for false discovery rate (30) 
** hydrocortisone dose; in patients taking prednisolone instead of hydrocortisone, the equivalent dose was 
calculated by multiplying total prednisolone dose by four (19).  
Table 2: Hospital Anxiety and Depression Scale and Quality of Life scores in the CAH patients 
and the controls matched for age, sex and educational status. 
Data presented as Median (Q1-Q3) CAH Controls p-value 
World Health Organization Quality of Life (QOL) questionnaire 
Number of participants 19  19   
QOL physical  92 (80-108) 128 (116-132) 0.000001* 
QOL psychological  72 (60-96) 92 (88-100) 0.049 
QOL social relationships 44 (36-52) 48 (40-52) 0.56 
QOL Environment  116 (108-136) 124 (108-136) 0.37 
QOL Total  90 (77-101) 108 (96-114) 0.001* 
Hospital Anxiety and Depression Scale (HADS) questionnaire 
HADS Anxiety  7 (5-11) 6 (4-8) 0.4 
HADS Depression  5 (3-7) 2 (1-3) 0.02* 
*p-values remain significant after controlling for false discovery rate (30) 
Table 3: Cognitive function assessments scores in the CAH patients and the controls matched 
for age, sex and educational status. 
Data presented as Median (Q1-Q3) CAH Controls p-value 
Wechsler Adult Intelligence Scale–Fourth Edition* 
Number of participants 18 19  
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15 
Full Scale IQ  94.5 (87-110) 110 (97-117) 0.09 
Perceptual Reasoning Index  103.2 (92.5-119) 104 (98-115) 0.6 
Verbal Comprehension Index  98.5 (82.5-110) 110 (87-112) 0.3 
Working Memory Index  92 (76.2-105) 100 (100-114) 0.04** 
Processing Speed Index  98.5 (89-113) 111 (102-120) 0.03** 
Digit span  7 (6-11) 10 (8-11) 0.04** 
Arithmetic  9.5 (5.7-12.2) 11 (9-13) 0.1 
Symbol search  10.5 (8-12) 11 (10-13) 0.1 
Coding  10 (7.8-12) 11 (10-15) 0.07 
Wechsler Memory Scales* 
Number of participants 19 19  
Design 1 Scaled  9 (7-11) 11 (9-14) 0.02** 
Design 2 Scaled  11 (9-12) 11 (10-16) 0.06 
Visual Repetition Scaled 1  11 (8-13)  10 (8-12)  0.61 
Visual Repetition Scaled 1  12 (9-15) 12 (10-14) 0.97 
Content scaled 1  10 (9-12) 12 (7-13) 0.4 
Content scaled 2  10 (8-12) 12 (10-15) 0.07 
Spatial scaled 1  10 (8-12) 12 (10-13) 0.13 
Spatial scaled 2  10 (9-13) 12 (9-15) 0.24 
Auditory memory index  100 (93-113) 109 (94-118) 0.27 
Visual memory Index  105 (95-112) 110 (100-117) 0.22 
Immediate memory index  102 (87-111) 109 (96-115) 0.16 
Delayed memory index  104 (98-114) 115 (104-123) 0.14 
* Results presented as median (Q1, Q3) corrected for educational level ** Whilst we had a priori hypotheses that 
working memory, processing speed and digit span would be reduced in patients with CAH based on previous studies 
these results did not remain significant after correction for false discovery rate  (17,32,34). 
Table 4: Neural volumes determined from T1-weighted MRI using Freesurfer, Results corrected 
for age at scan and total brain volume (25) and Spectroscopy acquired CNS metabolite 
concentrations; data analysed using TARQUIN (26) 
Data presented as Median (Q1-Q3) CAH Controls p-
value 
Number of participants 18 18  
Total brain volume (IQR) 1044732 (115246) 1069078 (86972) 0.47 
CSF  1013 (914-1302) 839 (750-918) 0.003* 
Left hippocampus  3792 (3611-4054) 4014 (3644-4271) 0.16 
Right hippocampus  3744 (3639-3969) 3981 (3682-4272) 0.028* 
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16 
Left amygdala  1509 (1406-1685) 1658 (1492-1848) 0.055 
Right amygdala  1680 (1524-1785) 1718 (1488-1958) 0.6 
Left thalamus  6318 (5894-6874) 6906 (6262-7578) 0.007* 
Right thalamus  6240 (5689-6730) 6622 (6333-7079) 0.008* 
Cerebellum (SD, SE) 113878 (106656-125254) 127499 (11484-134100) 0.014* 
Brainstem  19145 (17569-20910) 20527 (19863-21794) 0.03* 
Mesial temporal voxel metabolites 
Number of participants 17 16  
Glutamate 7.9 (6.2-10.3) 8 (4.9-10.8) 0.6 
Total NAA  5.6 (4.6-6.3) 6.1 (4.9-7.2) 0.1 
Total choline 1.9 (1.5-2.1) 2.3 (2-2.5) 0.001* 
Total creatine 6.8 (5.8-7.9) 8 (7.6-8.9) 0.04 
Glx   14.6 (11.2-18.3) 15 (11-16.9) 0.7 
Parietal voxel metabolites 
Number of participants 18 17 
 
Glutamate  3.7 (2.9-4.4) 3.6 (2.4-4.5) 0.8 
Total NAA  7.7 (7.2-8.8) 7.6 (7.3-8.6) 0.6 
Total choline 2 (1.6-2.2) 1.9 (1.7-2) 0.5 
Total creatine 6.4 (5.8-6.7) 6.1 (5.8-6.6) 0.6 
Glx  4.5 (3.1-7.2) 6.1 (3-8.4) 0.7 
*p-value remains significant after controlling for false discovery rate (30) 
AD
VA
N
CE
 A
RT
IC
LE
:
TH
E 
JO
UR
NA
L 
O
F 
CL
IN
IC
AL
 
EN
D
O
CR
IN
O
LO
G
Y 
& 
M
ET
AB
O
LI
SM
JC
EM
Downloaded from https://academic.oup.com/jcem/advance-article-abstract/doi/10.1210/jc.2017-01481/4642962
by University of East Anglia user
on 30 November 2017
AD
VA
N
CE
 A
RT
IC
LE
:
En
d
o
cr
in
o
lo
g
y
AD
VA
N
CE
 A
RT
IC
LE
:
En
d
o
cr
in
o
lo
g
y
AD
VA
NC
E 
AR
TI
CL
E
AD
VA
N
CE
 A
RT
IC
LE
:
TH
E 
JO
UR
NA
L 
O
F 
CL
IN
IC
AL
 
EN
D
O
CR
IN
O
LO
G
Y 
& 
M
ET
AB
O
LI
SM
JC
EM
Downloaded from https://academic.oup.com/jcem/advance-article-abstract/doi/10.1210/jc.2017-01481/4642962
by University of East Anglia user
on 30 November 2017
AD
VA
N
CE
 A
RT
IC
LE
:
En
d
o
cr
in
o
lo
g
y
AD
VA
N
CE
 A
RT
IC
LE
:
En
d
o
cr
in
o
lo
g
y
AD
VA
NC
E 
AR
TI
CL
E
AD
VA
N
CE
 A
RT
IC
LE
:
TH
E 
JO
UR
NA
L 
O
F 
CL
IN
IC
AL
 
EN
D
O
CR
IN
O
LO
G
Y 
& 
M
ET
AB
O
LI
SM
JC
EM
Downloaded from https://academic.oup.com/jcem/advance-article-abstract/doi/10.1210/jc.2017-01481/4642962
by University of East Anglia user
on 30 November 2017
